Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and with more aggressive tax and spending policy in the works, there a number of risks to biotech over the next 1-2 years out of Washington.
April 22, 2021 | LifeSciVC
Five Macro Risks To Biotech Coming Out of Washington
April 20, 2021 | LifeSciVC
Biotech Funding Tops The Charts Again
Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment.
April 15, 2021 | From the Trenches
Reimagining The Workplace Post Pandemic
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace. CEO’s that I have spoken with are gravitating towards a hybrid model that requires employees to be on site for specific days but not the entire week. This is consistent with a recent PWC survey (Figure 1) suggests that only 21% of employers feel that 5 days a week in the office is required to maintain a strong culture.
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC
April 8, 2021 | From the Trenches
Scaling Culture With Growth: How to maintain your startup’s “special sauce”
I’ve been thinking a lot about growth, and for good reason: Dyne is in the midst of a significant scale-up.
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC
April 1, 2021 | From the Trenches
Ode to Scientists
In the fall of 2019, I wrote a blog called Ode to Patients. As stresses from many directions have mounted over the past 12 months, it seems that paying heed to another group now makes sense: scientists.
By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC